Please Wait.....
Report
North America Dengue Treatment Market
Market Report I 2024-06-01 I 194 Pages I Data Bridge Market Research
North America dengue treatment market is expected to reach USD 311.62 million by 2031, from USD 143.29 million in 2023, growing at the CAGR of 10.2% in the forecast period of 2024 to 2031.
Market Segmentation:
North America Dengue Treatment Market, By Strains (DENV-2, DENV-3, DENV-1, DENV-4, and Others), Type (Vaccines and Acetaminophen), Severity (Mild to Moderate Dengue and Severe Dengue), Route of Administration (Parenteral and Oral), Mode of Purchase (Prescription and Over-the-Counter (OTC)), Gender (Male and Female), Age (Adult, Pediatric, and Geriatric), End User (Hospital, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies), By Countries (U.S., Canada, and Mexico) - Industry Trends and Forecast to 2031
Overview of North America Dengue Treatment Market Dynamics:
Driver
- Rising dengue incidence rate result in the demand for effective treatment
Restrain
- Delay in the approval process of vaccines
Opportunity
- Growing number of pipeline vaccines for dengue treatment
Market Players:
The key market players operating in the North America dengue treatment market are listed below:
- Sanofi
- Takeda Pharmaceutical Company Limited
- Viatris Inc.
- Johnson & Johnson
- GSK plc.
- Perrigo Company PLC
- Baxter
- Fresenius Kabi USA
- Pfizer
- Hikma Pharmaceuticals PLC
- Sun Pharmaceutical Industries Ltd
- Teva Pharmaceuticals USA, Inc.
- Aurobindo Pharma
1 INTRODUCTION 40
1.1 OBJECTIVES OF THE STUDY 40
1.2 MARKET DEFINITION 40
1.3 OVERVIEW OF THE NORTH AMERICA DENGUE TREATMENT MARKET 40
1.4 CURRENCY AND PRICING 42
1.5 LIMITATIONS 42
1.6 MARKETS COVERED 43
2 MARKET SEGMENTATION 46
2.1 MARKETS COVERED 46
2.2 GEOGRAPHICAL SCOPE 47
2.3 YEARS CONSIDERED FOR THE STUDY 48
2.4 DBMR TRIPOD DATA VALIDATION MODEL 49
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 52
2.6 MULTIVARIATE MODELLING 53
2.7 MARKET APPLICATION COVERAGE GRID 54
2.8 PRODUCT LIFELINE CURVE 55
2.9 DBMR MARKET POSITION GRID 56
2.10 VENDOR SHARE ANALYSIS 57
2.11 SECONDARY SOURCES 58
2.12 ASSUMPTIONS 58
3 EXECUTIVE SUMMARY 59
4 PREMIUM INSIGHTS 62
4.1 PESTEL ANALYSIS 63
4.2 PORTER'S FIVE FORCES 64
5 NORTH AMERICA DENGUE TREATMENT MARKET: REGULATIONS 65
5.1 U.S. REGULATORY SCENARIO FOR DENGUE TREATMENT 66
5.2 EUROPE REGULATORY SCENARIO FOR DENGUE TREATMENT 66
5.3 DEVELOPING COUNTRIES REGULATORY FRAMEWORK 67
5.4 LEGISLATION FOR CONTROL OF DENGUE IN SINGAPORE 67
5.5 DVCRN DEVELOPING VACCINE REGULATORS NETWORK 68
6 MARKET OVERVIEW 69
6.1 DRIVERS 71
6.1.1 RISING DENGUE INCIDENCE RATE RESULT IN THE DEMAND FOR EFFECTIVE TREATMENT 71
6.1.2 RISING WAVE OF DENGUE VACCINE LAUNCHES 71
6.1.3 GOVERNMENT INITIATIVES AND VACCINATION PROGRAMS 72
6.1.4 GROWTH OF MEDICAL INSURANCE IN EMERGING COUNTRIES 73
6.2 RESTRAINTS 74
6.2.1 DELAY IN THE APPROVAL PROCESS OF VACCINES 74
6.2.2 LACK OF AWARENESS AND HEALTHCARE INFRASTRUCTURE FOR TREATMENT OF DENGUE 75
6.2.3 DIFFICULTY IN THE DETECTION ASSAY FOR DENGUE 76
6.3 OPPORTUNITIES 77
6.3.1 STRATEGIC COLLABORATION WITHIN THE PHARMACEUTICAL INDUSTRY FUELS THE MARKET 77
6.3.2 GROWING NUMBER OF PIPELINE VACCINES FOR DENGUE TREATMENT 77
6.3.3 RISING R&D INVESTMENT AND ACTIVITIES 78
6.4 CHALLENGES 79
6.4.1 HEALTHCARE SERVICES ARE LIMITEDLY ACCESSIBLE IN RURAL AREAS 79
6.4.2 HIGH COSTS OF TREATMENT RESTRICT THE FEASIBILITY OF COST-EFFECTIVE SOLUTIONS 79
7 NORTH AMERICA DENGUE TREATMENT MARKET, BY STRAINS 81
7.1 OVERVIEW 82
7.2 DENV-2 85
7.3 DENV-3 85
7.4 DENV-1 86
7.5 DENV-4 86
7.6 OTHERS 87
8 NORTH AMERICA DENGUE TREATMENT MARKET, BY TYPE 88
8.1 OVERVIEW 89
8.2 VACCINES 92
8.2.1 DENGVAXIA (CYD-TDV) 93
8.2.2 QDENGA 93
8.3 ACETAMINOPHEN 93
8.3.1 PARENTERAL 94
8.3.2 ORAL 94
8.3.3 OTHER 94
9 NORTH AMERICA DENGUE TREATMENT MARKET, BY SEVERITY 95
9.1 OVERVIEW 96
9.2 MILD TO MODERATE DENGUE 99
9.3 SEVERE DENGUE 99
?
10 NORTH AMERICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 100
10.1 OVERVIEW 101
10.2 PARENTERAL 104
10.2.1 SUB-CUTANEOUS 104
10.2.2 INTRAVENOUS 104
10.3 ORAL 105
10.3.1 TABLET 105
10.3.2 CAPSULES 105
10.3.3 OTHERS 105
11 NORTH AMERICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE 106
11.1 OVERVIEW 107
11.2 PRESCRIPTION 110
11.3 OVER-THE-COUNTER (OTC) 110
12 NORTH AMERICA DENGUE TREATMENT MARKET, BY GENDER 111
12.1 OVERVIEW 112
12.2 MALE 115
12.3 FEMALE 115
13 NORTH AMERICA DENGUE TREATMENT MARKET, BY AGE 116
13.1 OVERVIEW 117
13.2 ADULT 120
13.3 PEDIATRIC 120
13.4 GERIATRIC 121
14 NORTH AMERICA DENGUE TREATMENT MARKET, BY END USER 122
14.1 OVERVIEW 123
14.2 HOSPITAL 126
14.3 SPECIALTY CLINICS 126
14.4 HOME HEALTHCARE 127
14.5 OTHERS 127
15 NORTH AMERICA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL 128
15.1 OVERVIEW 129
15.2 RETAIL PHARMACIES 132
15.3 HOSPITAL PHARMACIES 132
15.4 ONLINE PHARMACIES 133
?
16 NORTH AMERICA DENGUE TREATMENT MARKET, BY REGION 134
16.1 NORTH AMERICA 137
16.1.1 MEXICO 142
16.1.2 U.S. 147
16.1.3 CANADA 152
17 NORTH AMERICA DENGUE TREATMENT MARKET: COMPANY LANDSCAPE 157
17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 158
17.3 COMPANY SHARE ANALYSIS: EUROPE 159
17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 160
17.5 COMPANY SHARE ANALYSIS: SOUTH AMERICA 161
18 SWOT ANALYSIS 162
19 COMPANY PROFILE 163
19.1 SANOFI 163
19.1.1 COMPANY SNAPSHOT 163
19.1.2 REVENUE ANALYSIS 163
19.1.3 COMPANY SHARE ANALYSIS 164
19.1.4 PRODUCT PORTFOLIO 164
19.1.5 RECENT DEVELOPMENTS 164
19.2 TAKEDA PHARMACEUTICAL COMPANY LIMITED 165
19.2.1 COMPANY SNAPSHOT 165
19.2.2 REVENUE ANALYSIS 165
19.2.3 COMPANY SHARE ANALYSIS 166
19.2.4 PRODUCT PORTFOLIO 166
19.2.5 RECENT DEVELOPMENTS 166
19.3 VIATRIS INC. 168
19.3.1 COMPANY SNAPSHOT 168
19.3.2 REVENUE ANALYSIS 169
19.3.3 COMPANY SHARE ANALYSIS 169
19.3.4 PRODUCT PORTFOLIO 169
19.3.5 RECENT DEVELOPMENTS 170
19.4 JOHNSON & JOHNSON SERVICES, INC. 171
19.4.1 COMPANY SNAPSHOT 171
19.4.2 REVENUE ANALYSIS 171
19.4.3 COMPANY SHARE ANALYSIS 172
19.4.4 PRODUCT PORTFOLIO 172
19.4.5 RECENT DEVELOPMENT 172
?
19.5 GSK PLC. 174
19.5.1 COMPANY SNAPSHOT 174
19.5.2 REVENUE ANALYSIS 174
19.5.3 COMPANY SHARE ANALYSIS 175
19.5.4 PRODUCT PORTFOLIO 175
19.5.5 RECENT DEVELOPMENTS 175
19.6 AUROBINDO PHARMA 176
19.6.1 COMPANY SNAPSHOT 176
19.6.2 REVENUE ANALYSIS 176
19.6.3 PRODUCT PORTFOLIO 177
19.7 BAXTER 178
19.7.1 COMPANY SNAPSHOT 178
19.7.2 REVENUE ANALYSIS 178
19.7.3 PRODUCT PORTFOLIO 179
19.8 FRESENIUS KABI USA 180
19.8.1 COMPANY SNAPSHOT 180
19.8.2 PRODUCT PORTFOLIO 180
19.8.3 RECENT DEVELOPMENTS 180
19.9 HIKMA PHARMACEUTICALS 181
19.9.1 COMPANY SNAPSHOT 181
19.9.2 REVENUE ANALYSIS 181
19.9.3 PRODUCT PORTFOLIO 182
19.9.4 RECENT DEVELOPMENT 182
19.10 PERRIGO COMPANY PLC 183
19.10.1 COMPANY SNAPSHOT 183
19.10.2 REVENUE ANALYSIS 183
19.10.3 PRODUCT PORTFOLIO 184
19.10.4 RECENT DEVELOPMENT 184
19.11 PFIZER INC. 185
19.11.1 COMPANY SNAPSHOT 185
19.11.2 REVENUE ANALYSIS 185
19.11.3 PRODUCT PORTFOLIO 186
19.11.4 RECENT DEVELOPMENTS 186
19.12 SUN PHARMACEUTICAL INDUSTRIES LTD 187
19.12.1 COMPANY SNAPSHOT 187
19.12.2 REVENUE ANALYSIS 188
19.12.3 PRODUCT PORTFOLIO 188
19.12.4 RECENT DEVELOPMENT 188
?
19.13 TEVA PHARMACEUTICALS USA, INC. 189
19.13.1 COMPANY SNAPSHOT 189
19.13.2 REVENUE ANALYSIS 189
19.13.3 PRODUCT PORTFOLIO 190
19.13.4 RECENT DEVELOPMENT 190
20 QUESTIONNAIRE 191
21 RELATED REPORTS 194
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security